Addressing Localized Discomfort and Symptomatic Disruption

Braunol 10% is applied across therapeutic domains where additional symptomatic support is needed, used in situations involving symptoms related to physical discomfort. It is considered relevant for easing symptoms that interfere with daily comfort and is commonly used across conditions involving episodic or fluctuating manifestations. The active ingredient is considered relevant when supportive symptom management is appropriate. It is often used during phases when symptoms become more noticeable. This contributes to easing the overall symptom load and may assist with maintaining functional stability.

Quick Fact: Supports Easing Physical Discomfort

Supportive Care for Acute Episodes

It is generally applied in contexts involving symptoms associated with acute or episodic changes, and may be part of symptomatic management where short-term symptom stabilization is important. It is used in situations involving recurrent or acute episodes, particularly those characterized by symptoms that create noticeable physiological strain. It supports patients during difficult episodes, which contributes to easing the overall symptom load. It may assist with addressing symptom clusters that may become intense or disruptive and may help patients cope more steadily with symptom fluctuations.

Regulatory References

1. NIH DailyMed overview of Povidone-Iodine

Who Can and Cannot Use Braunol 10% (Povidone-Iodine)

Official regulatory guidelines strictly define the populations eligible to use Braunol 10% solution, primarily based on the risk of systemic iodine absorption impacting the thyroid. Use is generally established for adults and adolescents requiring short-term, topical antisepsis.

---

Absolute Contraindications (Must Not Use)

The solution is contraindicated and must not be used by individuals with the following conditions or characteristics:

• A known hypersensitivity or allergy to Povidone-Iodine or any ingredient.
• Any manifest thyroid disorder, including hyperthyroidism.
• Duhring's herpetiform dermatitis (a rare skin condition).
• Before or after radioiodine therapy.
• Infants and children under the age of 1 year.

---

Restricted and Conditional Use

Use is not recommended or requires special caution and monitoring in several vulnerable groups:

• Pregnancy and Lactation: Use should be avoided or strictly limited, especially after the first trimester, due to potential risks of fetal or neonatal thyroid dysfunction.
• Older Adults: Use requires caution, particularly if there is a history of goiter or a predisposition to thyroid issues, necessitating close monitoring.
• Renal Impairment: Patients with pre-existing renal impairment require special care, especially if the product is applied over large areas or for repeated application.

Interactions with other medicines and products

The interaction profile for Braunol 10% (Povidone-Iodine) is structured around two key areas: chemical incompatibility and the potential for systemic iodine absorption.

---

Pharmacokinetic and Chemical Interactions

The product must not be used simultaneously or immediately after the application of certain other substances due to a risk of reduced efficacy or adverse reactions. Co-administration must be avoided with mercury-containing disinfectants because the reaction can lead to the formation of mercury iodide, which carries a risk of caustic injury. Simultaneous use with enzymatic wound treatment agents, hydrogen peroxide, taurolidine, or silver-containing disinfectants should be avoided as the oxidizing effect of Povidone-Iodine can lead to a mutual reduction in the effectiveness of the products or the formation of silver iodide.

---

Systemic and Diagnostic Interactions

Regular, large-area application of Povidone-Iodine can lead to iodine absorption. This must be considered in patients receiving lithium preparations, as the absorbed iodine may promote a lithium-induced hypothyroidism. Furthermore, the oxidizing property can interfere with various diagnostic tests, leading to false-positive results (e.g., tests for blood or glucose in stool/urine). Povidone-Iodine can also interfere with thyroid function diagnostics and make subsequent radioiodine therapy impossible by reducing the thyroid's iodine uptake. A waiting period of 1 to 2 weeks after stopping use is typically required before carrying out a new thyroid scintigram.

How Braunol 10% Works

---

️ Direct Chemical Destruction by Free Iodine Release

The drug's mechanism is initiated by the sustained release of free elemental iodine (I2) from its povidone-iodine carrier complex. This iodine acts as a chemical oxidant, penetrating the cells of microorganisms and chemically reacting with their vital components.

---

Multi-Targeted Disruption of Microbial Cell Machinery

The free iodine destroys the organism by chemically denaturing and oxidizing essential biological molecules, including proteins, enzymes, fatty acids, and nucleic acids (DNA/RNA). This simultaneous, widespread attack compromises the microorganism's ability to perform critical functions such as cellular respiration and protein synthesis, resulting in the termination of the organism's viability.

---

️ Physiological Consequence of Broad-Spectrum Action

The non-selective, multi-site chemical action on microorganisms terminates their viability and ability to proliferate on the applied surface. This core physiological change—the termination of microbial viability—is the resulting physiological consequence of the drug's mechanism of action.

How to Use Braunol 10% (Povidone-Iodine Solution)

This section outlines the administration guidelines for Braunol 10%, defining how the solution is applied.

Administration Requirements

Guideline Entity	Official Instruction
Route of Administration	Topical Use Only (External application to skin, wounds, or mucous membranes).
Official Concentration	Use undiluted for skin antisepsis, pre-operative application, and surgical hand disinfection.
Dilution Rule	Dilutions for wound rinsing, washing, or bathing must be freshly prepared immediately prior to use and cannot be stored.
Contact Time	For skin antisepsis before injections or punctures, maintain contact time of at least 15 seconds. For surgical intervention, required contact time is generally 1 minute (or up to 10 minutes for sebaceous skin).

Procedural and Age-Specific Rules

Procedural Steps:

1. Apply the solution to completely wet the entire area being treated.
2. Ensure the solution remains wet for the full required contact time.
3. Prevent Pooling of the liquid, especially under the patient, to avoid skin irritation.
4. Reapply the solution if the characteristic brown color fades, as this indicates reduced effectiveness.

Special Population Restrictions:

• Neonates and Infants: Regular use is strongly discouraged for infants up to six months of age. Use should only occur under strict physician supervision, and thyroid function testing of the infant is necessary after application.
• Long-term/Large Area Use: Avoid prolonged use or application to large surface areas (e.g., more than 10% of the body for more than 14 days) without medical guidance, especially in individuals with known thyroid dysfunction.

Research evidence / Overview of studies for Braunol 10%

---

Evidence for use in Preoperative Skin Preparation

Research has examined Povidone-Iodine 10% (PVP-I) in the context of microbial count reduction on the skin before surgical and invasive procedures. The evidence base includes meta-analyses of randomized controlled trials (RCTs) and comparison studies. These efforts examined various outcomes, primarily focusing on the rates of surgical site infection (SSI).

Studies primarily monitored adult patient populations. Studies described measurements of microbial colony counts on the skin surface, following application, with patterns being consistently reported. When comparing Povidone-Iodine directly with certain other antiseptic formulations, the findings were mixed regarding specific SSI rate measurements.

Evidence for use in Intraoperative Wound Care

Individual RCTs and meta-analyses have evaluated the solution's use for surgical wound washing during an operation (Intraoperative Wound Irrigation, or IOWI). The main research examined outcomes related to the occurrence rate of surgical site infection (SSI), comparing the use of the study solution against non-medicated fluids like saline.

Studies explored this scenario primarily in adult patients where the wound had a risk of contamination. Multiple studies described patterns observed in SSI rates when the study solution was used for irrigation, compared to when non-medicated fluids were used. Research is ongoing to provide more current data on standardization and comparative performance.

---

What is Still Uncertain About the Research Base

The research base has several areas where certainty remains low. Comparative evidence is lacking against some current antiseptic technologies. The research provides limited insight into long-term outcomes, as follow-up durations were limited across many of the central studies (typically 30 days post-procedure).

Furthermore, data for certain groups remain insufficient, particularly concerning pediatric or pregnant populations. The evidence highlights what is known — and what is still uncertain — about the specific conditions under which the product was tested.

Key Studies & References

1. NIH DailyMed: Povidone-Iodine Solution (Used for regulatory context and general use)

How to Store and Dispose of Braunol 10%

The storage and disposal of Braunol 10% must adhere strictly to official regulatory guidelines to maintain product stability and ensure safety.

---

Official Storage Requirements

The solution must be stored at a temperature that does not exceed 30°C.

It is a mandatory safety requirement to keep the medicine out of the reach and sight of children.

Braunol 10% must not be used after the expiry date printed on the container label.

Disposal Instructions

Any unused product or associated waste material should be disposed of in accordance with local requirements established by regional health authorities.

Furthermore, environmental precautions must be followed to avoid release to the environment when discarding the product.